NASDAQ:MESO - Mesoblast Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.62 +0.05 (+0.76 %)
(As of 07/22/2018 04:00 PM ET)
Previous Close$6.62
Today's Range$6.62 - $6.70
52-Week Range$4.74 - $7.79
Volume45,929 shs
Average Volume79,402 shs
Market Capitalization$623.41 million
P/E Ratio-6.82
Dividend YieldN/A
Mesoblast logoMesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic


Debt-to-Equity Ratio0.06
Current Ratio3.46
Quick Ratio3.46


Trailing P/E Ratio-6.82
Forward P/E Ratio-12.98
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.41 million
Price / Sales258.67
Cash FlowN/A
Price / CashN/A
Book Value$6.03 per share
Price / Book1.10


EPS (Most Recent Fiscal Year)($0.97)
Net Income$-76,810,000.00
Net Margins-256.91%
Return on Equity-11.77%
Return on Assets-9.73%


Outstanding Shares94,170,000
Market Cap$623.41

Mesoblast (NASDAQ:MESO) Frequently Asked Questions

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

How were Mesoblast's earnings last quarter?

Mesoblast limited (NASDAQ:MESO) issued its earnings results on Thursday, May, 31st. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.02. The company earned $1.07 million during the quarter, compared to the consensus estimate of $0.35 million. Mesoblast had a negative return on equity of 11.77% and a negative net margin of 256.91%. View Mesoblast's Earnings History.

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release their next quarterly earnings announcement on Tuesday, September, 4th 2018. View Earnings Estimates for Mesoblast.

What price target have analysts set for MESO?

6 brokerages have issued 1-year target prices for Mesoblast's shares. Their predictions range from $6.00 to $23.00. On average, they anticipate Mesoblast's share price to reach $15.6667 in the next twelve months. This suggests a possible upside of 136.7% from the stock's current price. View Analyst Ratings for Mesoblast.

What is the consensus analysts' recommendation for Mesoblast?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Mesoblast stock?

Here are some recent quotes from research analysts about Mesoblast stock:
  • 1. Maxim Group analysts commented, "Mesoblast announced that the company entered into a partnership in (600535.SS – in chronic heart failure (CHF) and MPC-25-IC in acute myocardial infarction (AMI). We are factoring the China market into our model for HF and raising our price target to $16, from $14." (7/18/2018)
  • 2. According to Zacks Investment Research, "Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. " (7/4/2018)
  • 3. Cantor Fitzgerald analysts commented, "We rate Mesoblast Overweight. We believe the company’s platform of mesenchymal lineage cell (MLC) therapies has the potential to treat an array of diseases with currently significant unmet needs. Valuation Summary We arrive at our 12-month price target of $23/share by assessing the after-tax, risk-adjusted NPV of future cash flows from Mesoblast’s MLC platform. The probability-adjusted, fully taxed NPV (15% discount rate) of future cash flows through 2030 is $2.3 billion (~$23 per ADR), in our calculation." (6/21/2018)

Who are some of Mesoblast's key competitors?

Who are Mesoblast's key executives?

Mesoblast's management team includes the folowing people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 61)
  • Mr. Josh Muntner, Chief Financial Officer (Age 49)
  • Dr. Suzanne Lipe BSc (Hons), Ph.D., LLB, VP of Operations (Age 68)
  • Mr. Jonathan Richard Symonds, Head of Corp. Fin. & Strategy (Age 59)
  • Mr. Peter Howard BSc, LLB (Hons), Gen. Counsel & Corp. Exec. (Age 50)

When did Mesoblast IPO?

(MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Has Mesoblast been receiving favorable news coverage?

Headlines about MESO stock have trended somewhat positive on Sunday, Accern reports. The research group ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mesoblast earned a media sentiment score of 0.15 on Accern's scale. They also assigned media stories about the company an impact score of 45.55 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Mesoblast?

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $6.62.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $623.41 million and generates $2.41 million in revenue each year. The company earns $-76,810,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]

MarketBeat Community Rating for Mesoblast (NASDAQ MESO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  338
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MESO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MESO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.